Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PHASE 1 STUDY OF NEK7-DIRECTED MOLECULAR GLUE DEGRADER (MGD) MRT-8102 UNDERWAY, TO INVESTIGATE A POTENTIAL NOVEL THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY DISEASES DRIVEN BY THE NLRP3 INFLAMMASOME; INITIAL READOUT ANTICIPATED IN H1 2026 VAV1-DIRECTED MGD MRT-6160 ADVANCING TOWARD ANTICIPATED INITIATION OF MULTIPLE PHASE 2 STUDIES IN IMMUNE-MEDIATED DISEASES PHASE 1/2 STUDY OF GSPT1-DIRECTED MGD MRT-2359 ADVANCING IN HEAVILY PRETREATED, CASTRATION-RESISTANT PROSTATE CANCER PATIENTS; ADDITIONAL RESULTS ON TRACK FOR H2 2025 STRONG CASH POSITION EXPECTED TO FUND OPERATIONS INTO 2028 THROUGH MULTIPLE ANTICIPATED PROOF-OF-CONCEPT CLINICAL READOUTS BOSTON, AUG. 07, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY REPORTED BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025. WITH THE ADVANCEMENT OF OUR THIRD PROGRAM INTO CLINICAL DEVELOPMENT, WE CONTINUE TO EFFICIENTLY EXECUTE ACROSS OUR PORTFOLIO OF ONLY-IN-CLASS AND FIRST-IN-CLASS MOLECULAR GLUE DEGRADERS, SAID MARKUS WARMUTH, M.D.

MONTE ROSA THERAPEUTICS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

MRT-8102 PHASE 1 STUDY INCLUDES SINGLE AND MULTIPLE ASCENDING DOSE COHORTS IN HEALTHY VOLUNTEERS AND IS DESIGNED TO EVALUATE SAFETY, PHARMACOKINETICS, NEK7 PROTEIN DEGRADATION, AND OTHER KEY DOWNSTREAM PHARMACODYNAMIC MARKERS; INITIAL RESULTS ANTICIPATED IN H1 2026 ADDITIONAL PHASE 1 COHORT DESIGNED TO EVALUATE POTENTIAL EARLY PROOF OF CONCEPT IN SUBJECTS WITH INCREASED CARDIOVASCULAR DISEASE (CVD) RISK AND ELEVATED CRP BOSTON, MASS., JULY 21, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT THE FIRST SUBJECTS HAVE BEEN DOSED IN A PHASE 1 STUDY EVALUATING MRT-8102, A NEK7-DIRECTED MGD BEING DEVELOPED FOR THE TREATMENT OF INFLAMMATORY CONDITIONS DRIVEN BY THE NLRP3 INFLAMMASOME, IL-1, AND IL-6.

MONTE ROSA THERAPEUTICS ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 STUDY OF MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER FOR THE TREATMENT OF MULTIPLE INFLAMMATORY DISEASES

BOSTON, JULY 03, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THE PUBLICATION OF GROUNDBREAKING NEW DISCOVERIES FEATURED ON THE COVER OF SCIENCE. THE RESEARCH ARTICLE, MINING THE CRBN TARGET SPACE REDEFINES RULES FOR MOLECULAR GLUE-INDUCED NEOSUBSTRATE RECOGNITION, DETAILS HOW MONTE ROSA'S PROPRIETARY ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML) ENGINE HAS UNCOVERED A BROAD RANGE OF HUMAN PROTEINS POTENTIALLY ACCESSIBLE TO CEREBLON (CRBN)-BASED DEGRADATION, SPANNING DIVERSE PROTEIN DOMAINS AND CLASSES.

MONTE ROSA ANNOUNCES PUBLICATION IN SCIENCE OF KEY INSIGHTS THAT ENABLE NEXT GENERATION MOLECULAR GLUE DEGRADER MEDICINES

MONTE ROSA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER FOR THE TREATMENT OF MULTIPLE INF

MONTE ROSA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER FOR THE TREATMENT OF MULTIPLE INFLAMMATORY DISEASES

BOSTON, MAY 28, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT MARKUS WARMUTH, M.D., CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, JUNE 4, 2025, AT 12:50 P.M.

MONTE ROSA THERAPEUTICS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

VAV1-DIRECTED MRT-6160 PROGRAM ADVANCING TOWARD MULTIPLE PHASE 2 STUDIES, ENABLED BY PHASE 1 SAD/MAD STUDY DATA SUPPORTING BROAD POTENTIAL APPLICATION IN IMMUNE-MEDIATED DISEASES MRT-2359 PHASE 1/2 STUDY DATA DEMONSTRATE ENCOURAGING SIGNALS OF CLINICAL RESPONSE IN HEAVILY PRETREATED CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RESISTANT TO AR THERAPY; ADDITIONAL RESULTS EXPECTED IN H2 2025 MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADERTARGETING DISEASES DRIVEN BY IL-1 AND THE NLRP3 INFLAMMASOME, ON TRACK FOR IND FILING IN H1 2025 CYCLIN E1 (CCNE1) AND CDK2-DIRECTED MGD PROGRAMS FOR THE TREATMENT OFCCNE1-DRIVEN SOLID TUMORS AND ER+ BREAST CANCER ADVANCING TOWARD THE CLINIC; IND SUBMISSION ANTICIPATED IN 2026 STRONG CASH POSITION EXPECTED TO FUND OPERATIONS INTO 2028 THROUGH MULTIPLE ANTICIPATED PROOF-OF-CONCEPT CLINICAL READOUTS BOSTON, MAY 08, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY REPORTED BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025. WE'VE MADE SIGNIFICANT PROGRESS ACROSS OUR ENTIRE PORTFOLIO IN THE DEVELOPMENT OF OUR ONLY-IN-CLASS AND FIRST-IN-CLASS MOLECULAR GLUE DEGRADER THERAPEUTICS, TARGETING DISEASES POORLY ADDRESSED BY CONVENTIONAL PHARMACEUTICAL APPROACHES, SAID MARKUS WARMUTH, M.D.

MONTE ROSA THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

CDK2 MOLECULAR GLUE DEGRADER (MGD) IN COMBINATION WITH CDK4/6 INHIBITION AND ANTI-ESTROGEN THERAPY ACHIEVED SUPERIOR TUMOR REGRESSION IN VIVO COMPARED TO STANDARD OF CARE CDK4/6 INHIBITION AND ANTI-ESTROGEN THERAPY CDK2 MGD DELAYED RESISTANCE TO CDK4/6 INHIBITION IN VITRO AND DISPLAYED SUPERIOR SELECTIVITY VERSUS CLINICAL-STAGE CDK2 INHIBITORS BOSTON, APRIL 28, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC.(NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THE COMPANY WILL PRESENT PRECLINICAL DATA ON THE POTENTIAL OF ITS HIGHLY SELECTIVE CYCLIN-DEPENDENT KINASE 2 (CDK2)-DIRECTED MOLECULAR GLUE DEGRADER, MRT-51443, TO TREAT HR-POSITIVE/HER2-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025, BEING HELD APRIL 25-30 IN CHICAGO, IL. IN PRECLINICAL MODELS OF HR-POSITIVE/HER2-NEGATIVE BREAST CANCER, THE COMBINATION OF MRT-51443 WITH A CDK4/6 INHIBITOR AND ANTI-ESTROGEN THERAPY DROVE ROBUST TUMOR REGRESSIONS, DEMONSTRATING NOTABLY DEEPER TUMOR RESPONSES THAN THE STANDARD OF CARE COMBINATION ALONE, SAID SHARON TOWNSON, PH.D.

MONTE ROSA THERAPEUTICS PRESENTS PRECLINICAL DATA AT AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025 ON THE POTENTIAL OF ITS CDK2-DIRECTED MOLECULAR GLUE DEGRADER TO TREAT HR-POSITIVE/HER2-NEGATIVE BREAST CANCER

RESULTS OF THE MRT-6160 PHASE 1 SAD/MAD STUDY DEMONSTRATE DEEP VAV1 DEGRADATION OF GREATER THAN 90%, SIGNIFICANT T AND B CELL FUNCTIONAL INHIBITION AS WELL AS SIGNIFICANT INHIBITION OF CYTOKINE RELEASE FROM T AND B CELLS FOLLOWING EX-VIVO STIMULATION, AND FAVORABLE SAFETY/TOLERABILITY PROFILE; DATA SUPPORT CLEAR PATH TO PHASE 2 STUDIES AND BROAD POTENTIAL APPLICATIONS IN IMMUNE-MEDIATED DISEASES PHASE 1/2 STUDY OF MRT-2359 DEMONSTRATES ENCOURAGING SIGNALS OF CLINICAL RESPONSE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS RESISTANT TO AR THERAPY, INCLUDING CONFIRMED RECIST RESPONSE; CRPC COHORT WILL BE FOCUS MOVING FORWARD WITH ADDITIONAL PHASE 1/2 RESULTS EXPECTED IN H2 2025; DEPRIORITIZING FURTHER EXPANSION ARMS IN SCLC, NSCLC AND NE TUMORS MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER TARGETING DISEASES DRIVEN BY IL-1 AND THE NLRP3 INFLAMMASOME, ON TRACK FOR IND FILING IN H1 2025 STRONG CASH POSITION EXPECTED TO FUND OPERATIONS INTO 2028 THROUGH MULTIPLE ANTICIPATED PROOF-OF-CONCEPT CLINICAL READOUTS COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 8:00 A.M. ET BOSTON, MARCH 20, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY REPORTED A CLINICAL UPDATE, BUSINESS HIGHLIGHTS, AND FINANCIAL RESULTS FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2024.

MONTE ROSA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE INCLUDING NEW CLINICAL RESULTS FROM MRT-6160 AND MRT-2359 PROGRAMS

COMPANY TO PRESENT CLINICAL RESULTS FROM PHASE 1 SAD/MAD STUDY OF VAV1-DIRECTED MOLECULAR GLUE DEGRADER MRT-6160 AND PHASE 1/2 STUDY OF MRT-2359 IN MYC-DRIVEN SOLID TUMORS CONFERENCE CALL AND WEBCAST PLANNED FOR 8 A.M. ET ON MARCH 20, 2025 BOSTON, MARCH 11, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT A PIPELINE UPDATE INCLUDING CLINICAL RESULTS FROM ITS PHASE 1 SAD/MAD STUDY OF THE VAV1-DIRECTED MGD MRT-6160 AND ITS PHASE 1/2 STUDY OF MRT-2359 IN MYC-DRIVEN SOLID TUMORS.

MONTE ROSA THERAPEUTICS TO PRESENT PIPELINE UPDATE AND RELEASE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ON MARCH 20, 2025

BOSTON, FEB. 24, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT MARKUS WARMUTH, M.D., CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE ON MONDAY, MARCH 3, 2025, AT 2:30 P.M.

Monte Rosa Therapeutics, Inc.

GLUE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Monte Rosa Therapeutics, Inc.

GLUE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

GLUE